The use of CRISPR/Cas technology in disease diagnostics has also seen a surge, most notably after 2019. Cas9 remains the Cas protein of choice in CRISPR/Cas-based diagnostics with the most number of publications associated with it, though in recent years Cas12 appears to be catching up managing to exceed Cas9 in 2023. CRISPR/Cas-based diagnostics have found application in detecting pathogens such as Zika virus and MRSA as well as cancer markers.